<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Uniqure Nv — News on 6ix</title>
<link>https://6ix.com/company/uniqure-nv</link>
<description>Latest news and press releases for Uniqure Nv on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 02 Mar 2026 12:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/uniqure-nv" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b4dd78dffbe2df113574.webp</url>
<title>Uniqure Nv</title>
<link>https://6ix.com/company/uniqure-nv</link>
</image>
<item>
<title>uniQure Announces 2025 Financial Results and Provides Recent Company Updates</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-2025-financial-results-and-provides-recent-company-updates</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-2025-financial-results-and-provides-recent-company-updates</guid>
<pubDate>Mon, 02 Mar 2026 12:05:00 GMT</pubDate>
<description>~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent i</description>
</item>
<item>
<title>uniQure to Announce 2025 Financial Results</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-to-announce-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-to-announce-2025-financial-results</guid>
<pubDate>Mon, 23 Feb 2026 12:05:00 GMT</pubDate>
<description>~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET. The event will be webcast under the Events & Presenta</description>
</item>
<item>
<title>uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-updated-preliminary-amt-120500052</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-updated-preliminary-amt-120500052</guid>
<pubDate>Fri, 06 Feb 2026 12:05:00 GMT</pubDate>
<description>~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies</description>
</item>
<item>
<title>uniQure Announces Type A Meeting Scheduled with FDA</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-type-meeting-scheduled-120500404</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-type-meeting-scheduled-120500404</guid>
<pubDate>Fri, 09 Jan 2026 12:05:00 GMT</pubDate>
<description>LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease. “We</description>
</item>
<item>
<title>uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2025-12-04</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2025-12-04</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative</description>
</item>
<item>
<title>uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-third-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating</description>
</item>
<item>
<title>uniQure to Announce Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announce-third-quarter-2025-financial-results-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announce-third-quarter-2025-financial-results-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.</description>
</item>
<item>
<title>uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-closing-upsized-public-offering-and-full-exercise-underwriters</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-closing-upsized-public-offering-and-full-exercise-underwriters</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative</description>
</item>
<item>
<title>uniQure Announces Pricing of Upsized $300 Million Public Offering</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-pricing-upsized-300-million-public-offering-2025-09-26</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-pricing-upsized-300-million-public-offering-2025-09-26</guid>
<pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative</description>
</item>
<item>
<title>uniQure Announces $200 Million Proposed Public Offering</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-200-million-proposed-public-offering-2025-09-24</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-200-million-proposed-public-offering-2025-09-24</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative</description>
</item>
<item>
<title>uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-refinancing-existing-50-million-debt-and-securing-additional-125</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-refinancing-existing-50-million-debt-and-securing-additional-125</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and</description>
</item>
<item>
<title>uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-positive-topline-results-pivotal-phase-i-ii-study-amt-130-patients</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-positive-topline-results-pivotal-phase-i-ii-study-amt-130-patients</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared</description>
</item>
<item>
<title>uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-initial-amt-191-phase-i-iia-data-showing-sustained-increases-gal</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-initial-amt-191-phase-i-iia-data-showing-sustained-increases-gal</guid>
<pubDate>Fri, 05 Sep 2025 04:00:00 GMT</pubDate>
<description>~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first</description>
</item>
<item>
<title>uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-second-quarter-2025-financial-results-and-highlights-recent-company</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-second-quarter-2025-financial-results-and-highlights-recent-company</guid>
<pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
<description>~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of</description>
</item>
<item>
<title>uniQure to Announce Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announce-second-quarter-2025-financial-results-2025-07-22</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announce-second-quarter-2025-financial-results-2025-07-22</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.</description>
</item>
<item>
<title>uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-appointment-kylie-okeefe-chief-customer-and-strategy-officer-2025</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-appointment-kylie-okeefe-chief-customer-and-strategy-officer-2025</guid>
<pubDate>Wed, 11 Jun 2025 04:00:00 GMT</pubDate>
<description>~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-presents-clinical-case-study-first-patient-dosed-amt-260-refractory-mesial</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-presents-clinical-case-study-first-patient-dosed-amt-260-refractory-mesial</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to</description>
</item>
<item>
<title>uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-first-quarter-2025-financial-results-and-highlights-recent-company</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-first-quarter-2025-financial-results-and-highlights-recent-company</guid>
<pubDate>Fri, 09 May 2025 04:00:00 GMT</pubDate>
<description>~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally</description>
</item>
<item>
<title>uniQure to Announce First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announce-first-quarter-2025-financial-results-2025-05-05</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announce-first-quarter-2025-financial-results-2025-05-05</guid>
<pubDate>Mon, 05 May 2025 04:00:00 GMT</pubDate>
<description>~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE</description>
</item>
<item>
<title>uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease</title>
<link>https://6ix.com/company/uniqure-nv/news/uniqure-announces-fda-breakthrough-therapy-designation-granted-amt-130-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/uniqure-nv/news/uniqure-announces-fda-breakthrough-therapy-designation-granted-amt-130-treatment</guid>
<pubDate>Thu, 17 Apr 2025 04:00:00 GMT</pubDate>
<description>~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional</description>
</item>
</channel>
</rss>